What is Azafaros?
Azafaros B.V. operates at the intersection of advanced pharmacology and rare disease management, focusing specifically on lysosomal storage disorders. The company's core value proposition centers on its lead therapeutic candidate, nizubaglustat, an orally administered azasugar designed to modulate glycosphingolipid metabolism. By targeting the central nervous system with a dual mode of action, Azafaros addresses critical unmet needs for patients suffering from severe metabolic conditions. The organization maintains a rigorous commitment to scientific excellence, bridging the gap between complex biochemical research and tangible patient outcomes through a robust, innovation-led development strategy.
How much funding has Azafaros raised?
Azafaros has raised a total of $27.4M across 1 funding round:
Series A
$27.4M
Series A (2020): $27.4M with participation from BioMedPartners, BioGeneration Ventures B.V, and Forbion
Key Investors in Azafaros
BioMedPartners
An independent venture capital firm based in Basel, Switzerland, specializing in early-stage European biotech companies with highly innovative assets.
BioGeneration Ventures B.V
A specialized life sciences venture capital firm focused on building and scaling innovative healthcare companies.
Forbion
A leading European life sciences venture capital firm that invests in world-class drug discovery and development companies.
What's next for Azafaros?
With the recent infusion of capital, Azafaros is poised to transition into a more mature phase of clinical validation. The strategic roadmap likely involves scaling the development of nizubaglustat and expanding its research capabilities to address broader metabolic pathways. As the company moves forward, the focus will remain on navigating regulatory milestones and optimizing its therapeutic platform to ensure long-term commercial viability. This funding serves as a catalyst for the firm to strengthen its operational infrastructure and potentially explore further indications for its proprietary azasugar technology, ultimately aiming to redefine the standard of care for rare metabolic disorders.
See full Azafaros company page
